2011
Effects of Risperidone and Parent Training on Adaptive Functioning in Children With Pervasive Developmental Disorders and Serious Behavioral Problems
Scahill L, McDougle CJ, Aman MG, Johnson C, Handen B, Bearss K, Dziura J, Butter E, Swiezy NG, Arnold LE, Stigler KA, Sukhodolsky DD, Lecavalier L, Pozdol SL, Nikolov R, Hollway JA, Korzekwa P, Gavaletz A, Kohn AE, Koenig K, Grinnon S, Mulick JA, Yu S, Vitiello B, Network R. Effects of Risperidone and Parent Training on Adaptive Functioning in Children With Pervasive Developmental Disorders and Serious Behavioral Problems. Journal Of The American Academy Of Child & Adolescent Psychiatry 2011, 51: 136-146. PMID: 22265360, PMCID: PMC3941712, DOI: 10.1016/j.jaac.2011.11.010.Peer-Reviewed Original ResearchAdaptation, PsychologicalAdolescentAntipsychotic AgentsAsperger SyndromeAutistic DisorderChecklistChildChild Behavior DisordersChild Development Disorders, PervasiveChild, PreschoolCombined Modality TherapyCommunicationCooperative BehaviorDose-Response Relationship, DrugEducationFemaleHumansMaleRisperidoneSocialization
2009
Medication and Parent Training in Children With Pervasive Developmental Disorders and Serious Behavior Problems: Results From a Randomized Clinical Trial
Aman MG, Mcdougle CJ, Scahill L, Handen B, Arnold LE, Johnson C, Stigler KA, Bearss K, Butter E, Swiezy NB, Sukhodolsky DD, Ramadan Y, Pozdol SL, Nikolov R, Lecavalier L, Kohn AE, Koenig K, Hollway JA, Korzekwa P, Gavaletz A, Mulick JA, Hall KL, Dziura J, Ritz L, Trollinger S, Yu S, Vitiello B, Wagner A, Network F. Medication and Parent Training in Children With Pervasive Developmental Disorders and Serious Behavior Problems: Results From a Randomized Clinical Trial. Journal Of The American Academy Of Child & Adolescent Psychiatry 2009, 48: 1143-1154. PMID: 19858761, PMCID: PMC3142923, DOI: 10.1097/chi.0b013e3181bfd669.Peer-Reviewed Original ResearchConceptsPervasive developmental disorderClinical trialsClinical Global Impressions-Improvement scoreAberrant Behavior Checklist IrritabilityParallel-group clinical trialParent trainingBehavioral problemsDevelopmental disordersRisperidone doseRisperidone monotherapyHyperactivity/noncompliance subscaleSevere behavioral problemsCOMB groupPT sessionsQuestionnaire scoresHSQ scoresMedicationsGreater reductionChildrenPrimary measureRisperidoneSignificant reductionStereotypic behaviorScoresDose
2007
Psychopharmacology
Scahill L, Koenig K, Carroll DH, Pachler M. Psychopharmacology. Journal Of Child And Adolescent Psychiatric Nursing 2007, 20: 188-190. PMID: 17688557, DOI: 10.1111/j.1744-6171.2007.00112.x.Peer-Reviewed Original Research
2006
Children's Yale-Brown Obsessive Compulsive Scale Modified for Pervasive Developmental Disorders
SCAHILL L, MCDOUGLE CJ, WILLIAMS SK, DIMITROPOULOS A, AMAN MG, MCCRACKEN JT, TIERNEY E, ARNOLD LE, CRONIN P, GRADOS M, GHUMAN J, KOENIG K, LAM KS, MCGOUGH J, POSEY DJ, RITZ L, SWIEZY NB, VITIELLO B. Children's Yale-Brown Obsessive Compulsive Scale Modified for Pervasive Developmental Disorders. Journal Of The American Academy Of Child & Adolescent Psychiatry 2006, 45: 1114-1123. PMID: 16926619, DOI: 10.1097/01.chi.0000220854.79144.e7.Peer-Reviewed Original ResearchConceptsChildren's Yale-Brown Obsessive Compulsive ScalePervasive developmental disorderYale-Brown Obsessive Compulsive ScaleRepetitive behaviorsYale-Brown Obsessive Compulsive Scale ModifiedDevelopmental disordersPediatric Psychopharmacology Autism NetworkLower adaptive functioningInternal consistencyMeasures of irritabilityMedication-free childrenExcellent internal consistencyObsessive Compulsive Scale
2005
Acute and Long-Term Safety and Tolerability of Risperidone in Children with Autism
Aman MG, Arnold M, McDougle CJ, Vitiello B, Scahill L, Davies M, McCracken JT, Tierney E, Nash PL, Posey DJ, Chuang S, Martin A, Shah B, Gonzalez NM, Swiezy NB, Ritz L, Koenig K, McGough J, Ghuman JK, Lindsay RL. Acute and Long-Term Safety and Tolerability of Risperidone in Children with Autism. Journal Of Child And Adolescent Psychopharmacology 2005, 15: 869-884. PMID: 16379507, DOI: 10.1089/cap.2005.15.869.Peer-Reviewed Original ResearchConceptsSimpson-Angus Neurological Rating ScaleAbnormal Involuntary Movement ScaleAdverse eventsBody mass indexAcute trialTreatment-emergent adverse eventsTolerability of risperidoneCommon adverse eventsMost adverse eventsOpen-label extensionPlacebo-controlled trialMonths of treatmentUnanticipated adverse eventsSame adverse eventsLong-term safetyNeurological Rating ScaleOpen-label risperidoneRisperidone groupRisperidone therapyExtrapyramidal symptomsBlood assessmentMass indexPlacebo nonrespondersMovement ScaleLifetime diagnosisAssessment of the Integrity of Study Blindness in a Pediatric Clinical Trial of Risperidone
Vitiello B, Davies M, Arnold L, McDougle C, Aman M, McCracken J, Scahill L, Tierney E, Posey D, Swiezy N, Koenig K. Assessment of the Integrity of Study Blindness in a Pediatric Clinical Trial of Risperidone. Journal Of Clinical Psychopharmacology 2005, 25: 565-569. PMID: 16282839, DOI: 10.1097/01.jcp.0000185426.08268.92.Peer-Reviewed Original ResearchConceptsPlacebo treatment armsClinical evaluatorsAdverse eventsClinical trialsTreatment assignmentTreatment armsActual treatment assignmentPlacebo-controlled trialPediatric clinical trialsAdverse event dataLack of improvementActive treatmentOutcome dataPediatric psychopharmacologyIndividual treatment assignmentRisperidoneTrialsBlindnessParentsArmAutism
2002
Risperidone in Children with Autism and Serious Behavioral Problems
McCracken JT, McGough J, Shah B, Cronin P, Hong D, Aman MG, Arnold LE, Lindsay R, Nash P, Hollway J, McDougle CJ, Posey D, Swiezy N, Kohn A, Scahill L, Martin A, Koenig K, Volkmar F, Carroll D, Lancor A, Tierney E, Ghuman J, Gonzalez NM, Grados M, Vitiello B, Ritz L, Davies M, Robinson J, McMahon D. Risperidone in Children with Autism and Serious Behavioral Problems. New England Journal Of Medicine 2002, 347: 314-321. PMID: 12151468, DOI: 10.1056/nejmoa013171.Peer-Reviewed Original ResearchMeSH KeywordsAdolescentAntipsychotic AgentsAutistic DisorderChildChild BehaviorChild, PreschoolDouble-Blind MethodFemaleHumansMaleRisperidoneTreatment OutcomeConceptsClinical Global Impression-ImprovementAtypical antipsychotic agentsPlacebo groupSelf-injurious behaviorRisperidone groupAntipsychotic agentsAutistic disorderIrritability scoresDouble-blind trialPrimary outcome measureTreatment of adultsTraditional antipsychotic medicationsPercent decreaseSerious behavioral disturbancesAberrant Behavior ChecklistRisperidone therapyTardive dyskinesiaAntipsychotic medicationAverage weight gainOutcome measuresPositive responsePostsynaptic dopamineSerotonin receptorsBehavioral disturbancesSevere tantrums
2001
Methodological Issues in Designing a Multisite Trial of Risperidone in Children and Adolescents with Autism
Scahill L, McCracken J, McDougle C, Aman M, Arnold L, Tierney E, Cronin P, Davies M, Ghuman J, Gonzalez N, Koenig K, Lindsay R, Martin A, McGough J, Posey D, Swiezy N, Volkmar F, Ritz L, Vitiello B. Methodological Issues in Designing a Multisite Trial of Risperidone in Children and Adolescents with Autism. Journal Of Child And Adolescent Psychopharmacology 2001, 11: 377-388. PMID: 11838820, DOI: 10.1089/104454601317261555.Peer-Reviewed Original ResearchConceptsPlacebo-controlled studyPlacebo-controlled discontinuation studyAutistic disorderSafety of risperidoneStudy of RisperidoneStandard pharmacological treatmentSelf-injurious behaviorDiscontinuation studyPharmacological treatmentClinical trialsInclusion criteriaLong-term effectsSevere tantrumsTrial designClinical relevanceClinical practiceLength of trialRisperidoneMultisite trialStudy designContinuous treatmentTrialsTreatment effectsDisordersMaintenance phase
1999
Open-Label Quetiapine in the Treatment of Children and Adolescents with Autistic Disorder
Martin A, Koenig K, Scahill L, Bregman J. Open-Label Quetiapine in the Treatment of Children and Adolescents with Autistic Disorder. Journal Of Child And Adolescent Psychopharmacology 1999, 9: 99-107. PMID: 10461820, DOI: 10.1089/cap.1999.9.99.Peer-Reviewed Original ResearchMeSH KeywordsAdolescentAntipsychotic AgentsAutistic DisorderChildDibenzothiazepinesHumansMaleProspective StudiesQuetiapine FumarateWeight GainConceptsClinical Global Impression ScaleTreatment of childrenSide effectsAutistic disorderOpen-label trialShort-term safetyWeeks of treatmentGlobal Impression ScaleGlobal improvement itemSignificant side effectsSerious side effectsDSM-IV criteriaFurther dose increasesLack of responseMean ageImpression ScalePossible seizuresMale subjectsWeight gainBehavioral activationFourth weekQuetiapine fumarateDose increaseClinical populationsWeeksPharmacotherapy in Children and Adolescents With Pervasive Developmental Disorders
Scahill L, Koenig K. Pharmacotherapy in Children and Adolescents With Pervasive Developmental Disorders. Journal Of Child And Adolescent Psychiatric Nursing 1999, 12: 41-43. PMID: 10347430, DOI: 10.1111/j.1744-6171.1999.tb00040.x.Peer-Reviewed Original ResearchConceptsSide effectsNeuroleptic medicationAtypical neurolepticsLong-term side effectsNewer atypical neurolepticsRecurrent side effectsSerotonin reuptake inhibitorsExtrapyramidal side effectsUntoward side effectsLowest possible doseCourse of treatmentTreatment of childrenSevere behavioral difficultiesSelf-injurious behaviorMedication withdrawalReuptake inhibitorsMedication doseClinical benefitTraditional neurolepticsAbnormal movementsPossible doseTreatment planBaseline measurementsDepressed moodWeight gain